logo-loader

Wedbush looks to Fate Therapeutics and repeats ‘outperform’

Last updated: 10:04 09 Aug 2016 EDT, First published: 05:04 09 Aug 2016 EDT

shutterstock_234586750

Broker Wedbush is upbeat on Fate Therapeutics (NASDAQ:FATE) today and repeats an 'outperform' stance and an $8 a share target price.

The biotech firm reported a net loss of $9.2mln ($0.29 a share) in its latest quarter, which was better than the Wedbush estimate of ($0.35) and consensus of ($0.38) on lower than expected costs.

The group ended the three months with $45.9mln in cash and equivalents, not including the $10.3mln private placing, which it announced yesterday (Monday).

The broker believes near-term data for ProTmune Ph 1 study will likely be positive

"We believe additional positive catalysts for FATE could be provided by partnered programs entry into the clinic throughout 2017," it said.

San Diego based Fate specialises in immunotherapy treatments - a rapidly growing area of medicine, especially in cancer. Fates' cell therapy pipeline consists of immuno-oncology programs, including off-the-shelf NK- and T-cell cancer immunotherapies, which are made from engineered cells.

Also in US brokers today, Credit Suisse has upgraded pharma giant Merck (NYSE:MERK)  to 'outperform' from 'neutral' and repeated a target price of $73 a share.

Wunderlich moves EOG Resources (NYSE:EOG) to 'buy' from 'hold' and lifts the target to $104 from $79.

Agricultural behemoth Monsanto (NYSE:MON) is raised to 'buy' from 'neutral' by Monness Crespi & Hardt and the target repeated at $130.

Rush Rare Metals Advances Two Key Projects: Uranium in Wyoming and Niobium...

Rush Rare Metals CEO Peter Smith joined Steve Darling from Proactive to share news about the mineral exploration company's focus on its Boxi Property in Quebec and the Copper Mountain Project in Wyoming. The company recently announced the staking of the Knob claims in Wyoming, comprising 52...

31 minutes ago